Oral rivaroxaban for symptomatic venous thromboembolism.
By R. Bauersachs, S. Berkowitz, B. Brenner, H. Buller, H. Décousus, A. Gallus, A. Lensing, F. Misselwitz, M. Prins, G. Raskob and 9 more. New England Journal of Medicine, 2010
2,252 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/bc7c763b7fec782b3fe62af5c6e442e2019c83de
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
In Internal Medicine
Citations in the corpus
- Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. (2018, background): “Other sites 2 7 Venous and arterial events 10 (17) 8 (13) Pregnancy morbidity, n (%)† 16 (41) 12 (32)”
- Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “apixaban, and edoxaban), and secondary prevention of deep venous thrombosis or pulmonary embolism (rivaroxaban and apixaban only) [119–128].”
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE and no identifiable risk factor.(330,331,347,351) 353 IIa A”